A study to evaluate the role of metformin in preventing the incidence and complications of superimposed pre-eclampsia in chronic hypertensive patients

Role of metformin in preventing the incidence and complications of superimposed pre-eclampsia in chronic hypertensive patients - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/061712

Enrollment

Registered

2024-01-22

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O100- Pre-existing essential hypertension complicating pregnancy, childbirth and the puerperium

Interventions

Intervention1: T METFORMIN IN CHRONIC HYPERTENSIVE PATIENTS: T METFORMIN 500 MG BD IN CHRONIC HYPERTENSIVE PATIENTS FROM 14 WEEKS OF GESTATION TO 20 WEEKS OF GESTATION Control Intervention1: CHRONIC H

Eligibility

Inclusion criteria

Inclusion criteria: PREGNANT WOMEN WITH GESTATIONAL AGE BETWEEN 14 WEEKS TO 20 WEEKS BEING DIAGNOSED WITH CHRONIC HYPERTENSION WITHOUT PRE ECLAMPSIA SIGNS , SINGLETON PREGNANCY

Exclusion criteria

Exclusion criteria: MULTIPLE PREGNANCIES DIABETIC PATIENTS NON COOPERATION OF PATIENTS TO TAKE MEDICATION

Design outcomes

Primary

Measure	Time frame
metformin preventing the incidence of superimposed preeclampsia in chronic hypertensive patientsTimepoint: AT BASELINE ,AFTER 6 WEEKS OF GIVING TABLET METFORMIN IN CHRONIC HYPERTENSIVE PATIENTS AND TILL DELIVERY OF THE PREGNANT WOMEN	—

Secondary

Measure	Time frame
preventing iugr and other maternal and neonatal complications in chronic hypertensive patientsTimepoint: 10 months	—

Countries

India

Contacts

Public ContactDR A K KANMANI

THANJAVUR MEDICAL COLLEGE

drrrrpanju@gmail.com9487632069

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026